We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Can Halve Prostate Cancer Over-Diagnosis

By HospiMedica International staff writers
Posted on 29 Jul 2021
A new study suggests that screening by magnetic resonance imaging (MRI) and targeted biopsies could significantly reduce prostate cancer (PC) over-diagnosis. More...


Researchers at Karolinska Institutet (Solna, Sweden) and Karolinska University Hospital (Stockholm, Sweden) conducted a population-based study of 12,750 (50 to 74 years of age). Those with prostate-specific antigen (PSA) levels of 3 ng/ml or higher were randomly assigned to undergo standard biopsy or MRI, with targeted biopsy added if MRI results suggested PC. The primary outcome was proportion of men in whom clinically significant PC was diagnosed; a key secondary outcome was the detection of clinically insignificant cancers.

The results showed that 1,532 men had PSA levels of 3 ng/ml or higher; 603 were assigned to the standard biopsy group and 929 to the targeted biopsy group. In intention-to-treat analysis, clinically significant cancer was diagnosed in 21% in the targeted biopsy group, as compared with 18% in the standard biopsy group. The percentage of clinically insignificant cancers was lower in the targeted biopsy group (4%) than in the standard biopsy group (12%). The study was published on July 9, 2021, in The New England Journal of Medicine (NEJM).

“High rates of overdiagnosis are a critical barrier to organized PC screening. Most countries have not introduced nationwide PC screening, as current methods result in over-diagnoses and excessive and unnecessary biopsies,” said lead author urologist Tobias Nordström, PhD, of Karolinska Institutet. “Our results show that modern methods for PC screening maintain the benefits of screening, while decreasing the harms substantially. This addresses the greatest barrier to the introduction of nationwide screening.”

Current PC screening methods, which include prostate-specific antigen (PSA) tests combined with traditional biopsies, often result in unnecessary biopsies, and the detection of numerous minor low-risk tumors. Consequently, no country except Lithuania has chosen to introduce a nationwide PC screening programme, as the benefits do not exceed the disadvantages.

Related Links:
Karolinska Institutet
Karolinska University Hospital



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Desk Aneroid Sphyg
Diagnostix 750D+
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.